The Pan European Licensing Opportunity

Since 2000, there have been almost four times more product licensing deals signed for North America than for Europe. Granted, Europe is a more complex market, and the US produces a higher proportion of new drugs. But the figures spell a big opportunity for those firms able to offer truly pan-European scope and expertise.

Pharmaceutical product license deals for North America have significantly outnumbered those for Europe, even though both continents have seen an increase in transactions. (See Exhibit 1.) There are plenty of reasons for the discrepancy: the US is the world's largest and most profitable market, enjoys free pricing, and is relatively homogenous. Europe, on the other hand, is complex and fragmented, with strict price controls and cumbersome reimbursement systems.

Which isn't to say there aren't plenty of European companies seeking to in-license products in Europe. Yet few offer the...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

More from In Vivo